Diagonal Bio AB Cash Flow Conversion Efficiency
Diagonal Bio AB cash flow conversion efficiency. Based on the latest financial reports, Diagonal Bio AB (DIABIO) has a cash flow conversion efficiency ratio of -0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.27 Million ≈ $-244.50K USD) by net assets (Skr26.97 Million ≈ $2.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Diagonal Bio AB (2020–2024)
Cash flow conversion efficiency of Diagonal Bio AB from 2020 to 2024. This chart illustrates how Diagonal Bio AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Diagonal Bio AB (DIABIO) share price today for real-time trading data and today's change.
Diagonal Bio AB Cash Flow Conversion Ratio Explained
Diagonal Bio AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Diagonal Bio AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Diagonal Bio AB ranked by their cash flow conversion efficiency. Also see Diagonal Bio AB market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Element Lifestyle Retirement Inc
V:ELM
|
-0.003x |
|
Bridge Saas Ltd
AU:BGE
|
0.026x |
|
Works co uk PLC
LSE:WRKS
|
0.520x |
|
Shanti Overseas (India) Limited
NSE:SHANTI
|
-0.015x |
|
Silver Spruce Resources Inc
V:SSE
|
0.000x |
|
Greencastle Resources Ltd.
V:VGN
|
-0.014x |
|
Enersize Oy
ST:ENERS
|
0.057x |
|
Darmi Bersaudara Tbk PT
JK:KAYU
|
0.001x |
Annual Cash Flow Conversion Efficiency for Diagonal Bio AB (2020–2024)
The table below shows the annual cash flow conversion efficiency of Diagonal Bio AB from 2020 to 2024. Review DIABIO cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr24.59 Million ≈ $2.65 Million |
Skr-13.77 Million ≈ $-1.48 Million |
-0.560x | -127.33% |
| 2023-12-31 | Skr21.25 Million ≈ $2.29 Million |
Skr-5.23 Million ≈ $-562.94K |
-0.246x | +51.22% |
| 2022-12-31 | Skr31.25 Million ≈ $3.36 Million |
Skr-15.77 Million ≈ $-1.70 Million |
-0.505x | -56.20% |
| 2021-12-31 | Skr33.87 Million ≈ $3.64 Million |
Skr-10.94 Million ≈ $-1.18 Million |
-0.323x | -1367.78% |
| 2020-12-31 | Skr8.89 Million ≈ $957.03K |
Skr226.67K ≈ $24.39K |
0.025x | -- |
About Diagonal Bio AB
Diagonal Bio AB (publ) provides a point-of-care testing system for genetic markers that detects viruses, bacteria and fungi in Sweden. The company offers LAMPlify, a system used to identify the presence of specific genetic markers, such as fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid an… Read more